Spain: Internationalizing to offset domestic downturn
As a result of contractions in the domestic market following the European financial crisis, pharma companies based in Spain have been forced to look elsewhere for business, beyond the borders…
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Iberia, S.L.
Paseo de la Castellana 41 – 3a
28046 Madrid
Spain
Phone: +34 91 310 71 10
Fax: +34 91 310 71 11
www.biogenidec.es
As a result of contractions in the domestic market following the European financial crisis, pharma companies based in Spain have been forced to look elsewhere for business, beyond the borders…
José Antonio Crespo became general manager for Beckman Coulter Iberia in July 2013, following an extensive career at Siemens. He discusses the structural changes associated with the company’s acquisition by…
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
Manuel Díaz-Rubio, honorary president of Spain’s Royal Academy of Medicine, traces the history of Spain’s medical community over the last few decades, and emphasizes the importance of the pharmaceutical industry…
Joaquin Poch, president of the Royal Academy of Medicine of Spain, outlines the Academy’s history and current initiatives. What are the objectives of the Royal Academy of Medicine and…
Enrique Álvarez, President of Johnson & Johnson Spain, discusses how the affiliate has taken the necessary measures to adapt to the country’s newfound realities while still delivering only the best…
Enrique Álvarez, President of Johnson & Johnson Spain, discusses how the affiliate has taken the necessary measures to adapt to the country’s newfound realities while still delivering only the best…
Graham Skarnvad arrived to Spain as country manager of ALK’s Spanish affiliate at the end of 2009, right when the crisis was in full swing. Later on he took the…
Margarita Alfonsel, general secretary of the Spanish Federation of Healthcare Technology Companies (FENIN), discusses the state of the medtech sector in Spain today, outlining the industry’s biggest priorities and areas…
Maria Luisa Poncela has been the General Secretary of Science, Technology and Innovation under the Spanish Ministry of Economy since January 2012. In her role she fosters business competitiveness and…
For many years, Spain’s biotechnology sector was lagging behind the powerhouses of countries like the US and UK. Today, the sector touts a significantly different story, due to strategic investments…
Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more…
See our Cookie Privacy Policy Here